Related Experiment Video
Updated: May 9, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dabigatran and kidney disease: a bad combination
Felix Knauf1, C Michael Chaknos, Jeffrey S Berns
1Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Summary
Dabigatran, a direct thrombin inhibitor, poses bleeding risks without reversal agents. Managing dabigatran-related bleeding requires understanding its pharmacokinetics and exploring unproven methods like dialysis.
Area of Science:
- Pharmacology
- Cardiology
- Nephrology
Background:
- Dabigatran is an oral direct thrombin inhibitor for thromboembolic complications.
- Routine monitoring is unnecessary, but reversal agents are lacking.
- Increased bleeding risk, especially in the elderly, presents a clinical challenge.
Purpose of the Study:
- To review clinical management strategies for dabigatran-related bleeding.
- To discuss pharmacokinetic properties and monitoring of dabigatran.
- To evaluate dialytic and non-dialytic approaches for bleeding reduction.
Main Methods:
- Review of clinical data and pharmacokinetic profiles.
- Analysis of laboratory monitoring and anticoagulant effect assessment.
- Evaluation of hemodialysis and continuous renal replacement therapy efficacy.
Main Results:
- No reliable reversal agent exists for dabigatran's anticoagulant effect.
- Hemodialysis is explored for dabigatran removal, but its efficacy in reversing effects is unproven.
- Clinical approach to managing serious bleeding remains uncertain.
Conclusions:
- Clinicians face challenges managing dabigatran-induced bleeding due to lack of reversal agents and monitoring tests.
- Hemodialysis and CRRT are potential but unproven methods for dabigatran removal.
- Further research is needed to establish optimal management strategies for bleeding patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:09Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...